ERIC 2018 Session VII

Biomarker-aided Clinical Decision Making in CLL: Conclusions from the Workshops and Future Perspectives

Session VII of ERIC 2018 meeting provides us with a stimulating set of conclusions following the workshops on the implementation of biomarkers in the clinical environment.
Blanca Espinet, PhD, and Claudia Haferlach, MD, PhD, present conclusions on cytogenetics and Lesley Ann Sutton, PhD, discusses recurrent gene mutations.
Alessandra Tedeschi, MD, discusses clinical considerations for tailored treatment, while Davide Rossi, MD, PhD, explores the art of synthesis in the prognostication in CLL.

Presentations
Conclusions on Cytogenetics
Blanca Espinet, PhD
Hospital del Mar Institute of Medical Research, Barcelona, Spain
Claudia Haferlach, MD
Munich Leukemia Laboratory, Munich, Germany
27 October, 2018

Blanca Espinet, PhD, from Hospital del Mar Institute of Medical Research, Barcelona, Spain, and Claudia Haferlach, MD, from Munich Leukemia Laboratory, Munich, Germany discusses conclusions on cytogenetics.

Conclusions on Recurrent Gene Mutations
Lesley Ann Sutton, PhD
Karolinska Institute, Solna, Stockholm, Sweden
27 October, 2018

Lesley Ann Sutton, from Karolinska Institute, Solna, Stockholm, Sweden, talks about a presentation with Jitka Malčíková, PhD, Masaryk University, Brno, Czech Republic, on recurrent gene mutations.

Tailoring Treatment: Clinical Considerations
Alessandra Tedeschi, MD
Niguarda Cancer Center, Milan, Italy
27 October, 2018

Alessandra Tedeschi, MD, from Niguarda Cancer Center, Milan, Italy, discusses tailoring treatment: clinical considerations. Francesc Bosch, MD, PhD, from Vall d’Hebron Institute of Oncology, Barcelona, Spain and Florence Cymbalista, Avicenne Hospital, Bobigny, France, were co-authors.

Prognostication in CLL: the Art of Synthesis
Davide Rossi, MD, PhD
Institute of Southern Switzerland, Bellinzona, Switzerland
27 October, 2018

Davide Rossi, MD, PhD, from the Institute of Southern Switzerland, Bellinzona, Switzerland, talks on Prognostication in CLL.